SEC Comment Letter 0000000000-23-005535 to Harpoon Therapeutics, Inc. (CIK 0001708493)
Harpoon Therapeutics, Inc. (CIK 0001708493)
Date: May 24, 2023 · CIK: 0001708493 · Accession: 0000000000-23-005535
AI Filing Summary & Sentiment
File numbers found in text: 333-272064
Letter
United States securities and exchange commission logo May 24, 2023 Julie Eastland President and Chief Executive Officer Harpoon Therapeutics, Inc. 131 Oyster Point Blvd, Suite 300 South San Francisco, CA 94080 Re:Harpoon Therapeutics, Inc. Registration Statement on Form S-3 Filed May 19, 2023 File No. 333-272064 Dear Julie Eastland: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marina Remennik
Show Raw Text
United States securities and exchange commission logo
May 24, 2023
Julie Eastland
President and Chief Executive Officer
Harpoon Therapeutics, Inc.
131 Oyster Point Blvd, Suite 300
South San Francisco, CA 94080
Re:Harpoon Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 19, 2023
File No. 333-272064
Dear Julie Eastland:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marina Remennik